EMA Recommends Revoking Amgen Rare-Drug Approval, Pressuring Stock

Key Facts

In a negative regulatory development for the rare-disease drug sector, the European Medicines Agency (EMA) recommended revoking the marketing authorisation for Amgen's (AMGN) Tavneos, a treatment for rare autoimmune diseases. The recommendation followed the agency's conclusion that the drug's benefits do not outweigh its risks, according to a Reuters report.

Tavneos accounts for a relatively small portion of Amgen's total revenue, but the decision highlights the regulatory risks facing rare-disease drugs, as the EMA demands clear evidence of a favorable benefit-risk balance. The move comes as Amgen faces pressure to bolster its pipeline following patent expirations on some of its key drugs.